Immunoscore and beyond: evolution and clinical integration of immune contexture-based biomarkers across solid tumours - Takeaways - MDSpire

Immunoscore and beyond: evolution and clinical integration of immune contexture-based biomarkers across solid tumours

  • By

  • Esteban Orenes-Piñero

  • Silverio Ros-Martínez

  • José Luis Alonso-Romero

  • Juan Antonio Ortega-García

  • May 8, 2026

  • 0 min

Share

  • 1

    The Immunoscore (IS) assesses CD3+ and CD8+ T cells in tumours, enhancing cancer prognosis beyond traditional TNM staging.

  • 2

    IS has been validated in colorectal cancer and adapted for various solid tumours, showing improved survival correlation.

  • 3

    High IS scores generally indicate better patient outcomes, but inter-study variability limits comparability and reproducibility.

  • 4

    The integration of immune contexture metrics with genomic and imaging biomarkers is essential for precision oncology.

  • 5

    Current limitations in IS implementation include methodological heterogeneity and the need for prospective validation.

Original Source(s)

Immunoscore and beyond: evolution and clinical integration of immune contexture-based biomarkers across solid tumours

  • by Esteban Orenes-Piñero, Silverio Ros-Martínez, José Luis Alonso-Romero, Juan Antonio Ortega-García

  • May 8, 2026

Related Content

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment

Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report

FEBAIR microsurgical principles in meningiomas and recurrence: a long-term follow-up series